Clinical Trial Update: A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

View source ↗

Summary

This document describes a post-marketing observational study of Tasfygo for unresectable biliary tract cancer with FGFR2 fusion after chemotherapy, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Tasfygo

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Biliary Tract Cancer | Status: RECRUITING